Europe - France

HBC Avocats

We only have limited information for this firm. Consider the following firms which have provided more information:

Praised for its ‘creativity’ and ’great’ expertise, the team at HBC Avocats maintains a strong reputation for its capabilities in the negotiation and structuring of the full spectrum of transactions; the group regularly assists clients with contract manufacturing, technology transfer, and clinical trial agreements. Practice co-head Jonathan Burnham primarily advises life sciences companies on the drafting and negotiation of commercial agreements, and is praised for his ‘very strong’ expertise. Erwan Cossé is known for his vast knowledge of M&A and venture capital-related issues, assisting a number of biotech clients.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Very in-depth knowledge of the life sciences sector, ability to negotiate and draft contracts.’

  • ‘Jonathan Burnham is educational, efficient and able to move forward quickly on complex contract markups. Fabrice Herbin has excellent knowledge of the CRO and clinical studies sector. The team is an expert in its field, capable of moving forward quickly and efficiently at a very reasonable cost compared to large structures.’

Abbreviated data is displayed for this firm.

Key clients

  • Inotrem
  • Sanofi

Abbreviated data is displayed for this firm.

Work highlights

  • Advised Emergence Therapeutics, a French and German biotech company, on the drafting and negotiating of a license agreement to obtain access to the Dutch biotech company Synaffix’s proprietary antibody drug conjugate (ADC) technology platform for use with ADC products developed by Emergence.
  • Advised Memo Therapeutics AG, a Swiss biotech company specialised in antibody discovery, on the structuring, drafting and negotiation of a research and development collaboration and license agreement with the Japanese pharmaceutical company Ono Pharmaceutical, aimed at discovering, validating and developing antibodies in the field of immuno-oncology.

Abbreviated data is displayed for this firm.